Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Pharm Res. 2014 Nov 13;32(5):1663–1675. doi: 10.1007/s11095-014-1565-2

Figure 4. P-S is more efficacious against lewis lung carcinoma (LLC) in Ces −/− mice.

Figure 4

(A) Efficacy of P-S (150mg/kg, i.p.) in wild-type (left) and Ces1c −/− mice (right) bearing subcutaneous LLC tumors. (B) Efficacy of PLA-PEG P-S (50mg/kg, i.v.) and Pluronic P123 P-S (50mg/kg, i.v.) in wild-type (left) and Ces1c −/− (right) mice bearing subcutaneous tumors. (C) Representative images (left) of the mice and tumors treated with vehicle or P-S (150mg/kg, i.p.), tumor drug levels at end point (right). (D) Tumor drug levels of mice treated with PLA-PEG P-S (left) and Pluronic P123 (right). *, p<0.05.